PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
22.78%
Cost growth of 22.78% while AVXL maintains flat costs. Bruce Berkowitz would investigate efficiency gap.
-30.37%
Gross profit decline while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive position.
-30.37%
Margin decline while AVXL shows 0.00% expansion. Joel Greenblatt would examine competitive position.
45.24%
R&D growth above 1.5x AVXL's 7.77%. Michael Burry would check for spending discipline.
-4.95%
G&A reduction while AVXL shows 9.27% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.69%
Operating expenses growth above 1.5x AVXL's 8.15%. Michael Burry would check for inefficiency.
24.69%
Total costs growth above 1.5x AVXL's 8.15%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
22.78%
D&A growth above 1.5x AVXL's 10.22%. Michael Burry would check for excessive investment.
-24.88%
EBITDA decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-24.88%
EBITDA margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-24.83%
Operating income decline while AVXL shows 4.87% growth. Joel Greenblatt would examine position.
-24.83%
Operating margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
291.57%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
-21.98%
Both companies show declining income. Martin Whitman would check industry conditions.
-21.98%
Pre-tax margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-17.79%
Both companies show declining income. Martin Whitman would check industry conditions.
-17.79%
Net margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-12.12%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-9.09%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
5.06%
Share count reduction below 50% of AVXL's 1.57%. Michael Burry would check for concerns.
6.04%
Diluted share reduction below 50% of AVXL's 1.57%. Michael Burry would check for concerns.